Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
Capitol Connections Article Pittsburgh Study 11.15.13
Share |

American Journal of Obstetrics and Gynecology Reports on New 17-P Study

From the American Journal of Obstetrics and Gynecology, and what IACP, the FDA and compounding pharmacists have been saying all along: "Compounded Medication to Prevent Preterm Birth Not a Safety Risk, University of Pittsburgh Study Confirms."
Excerpted from this article: ""Contrary to the report provided by the company that markets Makena, we found that 17-OHPC from compounding pharmacies raised no safety concerns about drug potency, sterility or purity," said Steve N. Caritis, M.D., professor of obstetrics and gynecology at Pitt, and the study's corresponding author. Dr. Caritis cautioned, however, that the sample size was small and the findings cannot be applied to all compounded products or pharmacies."
Association Management Software Powered by YourMembership  ::  Legal